The CHARGE Act of 2025 establishes a $50 million annual grant program (2026-2030) to fund solar energy systems and energy storage technologies at Federally Qualified Health Centers (FQHCs). Eligible recipients - including FQHCs, state/local governments, or nonprofits representing FQHCs - can use grants to install renewable energy systems or receive technical assistance for their design and operation. The program, administered by the Department of Energy, directly supports community health centers in improving energy resilience and reducing operating costs. It specifically targets FQHCs serving underserved populations, as defined under the Social Security Act.
This bill expands Medicare's definition of "rural emergency hospital" to allow certain closed rural hospitals to rejoin the program. Specifically, it creates a new eligibility category for facilities that were critical access hospitals or rural hospitals (under Section 1886(d)) in rural counties, ceased operations between January 2014 and December 2020, and submit an application to become rural emergency hospitals. The bill modifies Medicare payment rules to provide specific adjustments for these reactivated facilities, including distance requirements (e.g., hospitals within 35 miles of another hospital won't receive immediate payment increases). The changes take effect January 1, 2027, directly affecting rural hospitals that closed during the specified period and wish to rejoin Medicare.
The Thalidomide Survivors Compensation Act of 2025 would establish a federal program to provide $150,000 in compensation to U.S. citizens or permanent residents who suffered birth defects from thalidomide exposure in utero during the 1950s-1960s. To qualify, individuals must submit documentation of exposure and injury by May 31, 2034, and the compensation would be tax-exempt and not count toward income calculations for means-tested welfare programs. The Department of Health and Human Services would administer the program, with an annual review process to evaluate its effectiveness and make adjustments as needed. The bill acknowledges approximately 100 U.S. thalidomide survivors remain alive today, facing ongoing medical needs without formal compensation, while 46 countries already provide such support to affected individuals.
This bill creates a 50% tax credit for individuals purchasing qualified mobility devices, such as wheelchairs, walkers, canes, braces, or prosthetics. The credit applies to costs paid after the bill's enactment, covers up to three devices per year, and prevents double benefits by reducing other deductions for the same expenses. It directly affects people who buy these devices for mobility needs, allowing them to claim the credit on their federal income tax returns. The credit is designed to offset out-of-pocket costs for essential mobility equipment.
The FASD Respect Act (S 139) establishes a federal program within the Public Health Service Act to improve support for individuals with fetal alcohol spectrum disorders (FASD) and their families. It creates FASD Centers for Excellence to expand diagnostic capacity, develop culturally appropriate interventions, and build state/Tribal partnerships for prevention, screening, and treatment. The law requires funding for public awareness campaigns, training for healthcare and social service professionals, and a national directory of FASD resources. This directly affects individuals with FASD, their families, healthcare providers, and state/Tribal health programs through new federal grants and coordination requirements.
This bill (HR 6868) streamlines the FDA review process for over-the-counter (OTC) drugs by requiring the agency to use the "least burdensome" approach when evaluating manufacturer requests to add new products to standardized OTC safety guidelines. It mandates that the FDA meet with companies if existing data is insufficient, provide written recommendations for necessary studies, and document these meetings in the public administrative record. The bill directly affects drug manufacturers seeking to market new OTC products, reducing review barriers without changing safety standards or altering the criteria for FDA approval. This focuses on improving efficiency in the regulatory process for OTC drug innovations.
HR 6652, the "U.S. Vets of the FAS Act," requires the Department of Veterans Affairs (VA) to provide telehealth services and mail-order pharmacy deliveries to veterans residing in the Freely Associated States (FAS) - which include the Marshall Islands, Micronesia, and Palau. The bill mandates the VA to establish agreements with FAS governments within one year of enactment and begin offering these services within the same timeframe. It also modifies travel payment rules to require VA to cover beneficiary travel costs starting one year after enactment. The VA must report quarterly on implementation progress and costs to Congress until agreements are finalized and services launched. This bill directly affects veterans in FAS territories and VA operations related to their healthcare access.
This bill amends the Higher Education Act to require colleges and universities receiving federal funds to implement evidence-based programs preventing alcohol and substance misuse among students and staff, replacing outdated terms like "drug abuse" with "substance misuse." It establishes a $15 million annual grant program (2027-2031) to fund recovery support services, integrated mental health and substance use care, overdose prevention, and campus-wide crisis response training. Institutions must certify compliance with these programs and report on implementation to Congress. The law directly affects all eligible higher education institutions, mandating updated prevention frameworks and collaboration with health agencies.
HR 5736, the PAVE Act, requires Medicare beneficiaries aged 65 and older to receive penicillin allergy verification during their initial preventive physical exam and annual wellness visit. The bill mandates that healthcare providers identify patients reporting a penicillin allergy, evaluate whether the reported reaction was a true allergy, explain the health risks of a false allergy label, and refer to specialists when needed. This verification process, effective January 2027, aims to correct false allergy labels - over 90% of which are inaccurate - improving antibiotic choices and patient outcomes. It directly affects seniors covered by Medicare who have self-reported penicillin allergies, with no cost to patients for this service.
S 822, the Scientific EXPERT Act of 2025, establishes a new process for FDA-led meetings focused on drug development for rare diseases. It requires a Foundation to convene at least four annual "science-focused drug development meetings" each year, bringing together researchers, drug sponsors, patient groups, and FDA review staff to address scientific challenges like clinical trial design and biomarker use for rare conditions. The bill mandates public summaries of meeting outcomes and requires the FDA to disclose how input from these meetings influenced drug approval decisions. This directly affects FDA review divisions, rare disease drug developers, and patient advocacy groups by creating a structured forum to align on development strategies for unmet medical needs. The program is funded with $1 million annually from fiscal years 2025-2029.
